Did You Know...
...that while attempting to develop a super strong glue, 3M employee Spencer Silver accidentally developed a glue that was so weak it would barely hold two pieces of paper together? However, his colleague Art Fry needed the glue. Fry sang with his church choir and marked the pages of his hymnal with small scraps of paper that often fell out. He used Silver's glue to hold the papers in place. Today we call this invention Post-it Notes.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7919577 | Adrenocorticotropic hormone analogs and related methods ACTH analog compounds of the present invention include compounds comprising an ACTH peptide sequence with one or more structural modifications that can have one or more of the following preferred ACTH analog biological functions: (1) reduction of corticosteroid secr... | 04/05/2011 |
| 7358225 | Cloning and recombinant production of CRF receptor(s) In accordance with the present invention, there are provided novel G-protein-coupled receptor proteins (CRF-R) characterized by having sufficient binding affinity for corticotropin releasing factor (CRF) such that concentrations of £ 10 nM of CRF occupy 3 | 04/15/2008 |
| 7141546 | CRFR2 selective ligands CRF peptide analogs that bind to CRFR2 with an affinity far greater than they bind to CRFR1. These analogs exhibit CRF antagonist activity, and they can be based upon the native structures of sauvagine, CRF, and urocortin. ... | 11/28/2006 |
| 7071161 | Variants of corticotropin releasing hormone receptor Type 1 and uses thereof The present invention identifies four new isoforms of human corticotropin releasing hormone receptor type 1 (CRH-R1e, 1f, 1g and 1h) and three new isoforms of mouse corticotropin releasing hormone receptor type 1 (mCRH-R1c, 1e and 1f). The data indicate that polymor... | 07/04/2006 |
| 6951655 | Pro-micelle pharmaceutical compositions The present invention provides pro-micelle compositions comprising a pharmaceutically active agent encapsulated with a membrane of esterified C12-C18 fatty acids. In the mammalian intestine, exposure to C12-C18 fatty acids... | 10/04/2005 |
| 6936585 | Corticotropin releasing factor 2 receptor agonists Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy. ... | 08/30/2005 |
| 6852834 | Fusion peptides isolatable by phase transition Genetically-encodable, environmentally-responsive fusion proteins comprising ELP peptides. Such fusion proteins exhibit unique physico-chemical and functional properties that can be modulated as a function of solution environment. The invention also provides methods... | 02/08/2005 |
| 6803359 | Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs The glutamic acid residue of corticotropin-releasing hormone analogs have had the position 20 amino acid residue replaced with a D-amino acid moiety. The resulting CRH analogs do not significantly lower blood pressure but have anti-proliferative actions in cell cult... | 10/12/2004 |
| 6699838 | Antiangiogenic peptides Mammalian kringle 5 fragments and kringle 5 fusion proteins are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.... | 03/02/2004 |
| 6534503 | Melanocortin receptor-3 ligands to treat sexual dysfunction Methods for treating sexual dysfunction, such as erectile dysfunction or sexual arousal disorder, with a compound having the generic formula X1 --X2 -(D)Phe-Arg-(D)Trp-X3. A particularly useful compound is HP-228, which ha... | 03/18/2003 |
| 6500934 | Bivalent agonists for G-protein coupled receptors Bivalent agonists having affinity for one or more G-protein coupled receptors, comprising two agonist or two antagonist ligand domains, wherein the distance between the ligand domains can range from about 40 to about 250 Å, and further comprising a backb... | 12/31/2002 |
| 6448032 | Human melanocyte stimulating hormone receptor polypeptide and DNA Novel DNA fragments encoding novel polypeptides having properties of melanotropic hormone receptors, especially DNA molecules encoding melanocyte stimulating hormone receptors (MSH receptors), as well as polypeptides which are MSH receptors, are disclosed... | 09/10/2002 |
| 6326463 | Cyclic CRF agonists Novel cyclic CRF agonist peptides have the amino acid sequence: (cyclo 30-33)Ac-Ser-Leu-Asp-Leu-Thr-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala -Arg-Ala-Glu-Gln-Leu-Ala-Gln-Glu-Ala-R32 -R33 -Asn-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH2 | 12/04/2001 |
| 6323312 | Cyclic CRF antagonist peptides Novel cyclic CRF antagonist peptides are created by shortening the N-terminus of a CRF family peptide by 8 residues and adding an acyl group. CML is present in what would be the 27-position of the native CRF sequence, and a cyclizing bond is created betwe... | 11/27/2001 |
| 6319900 | Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs The glutamic acid residue of corticotropin-releasing hormone analogs have had the position 20 amino acid residue replaced with a D-amino acid moiety. The resulting CRH analogs do not significantly lower blood pressure but have anti-proliferative actions i... | 11/20/2001 |
| 6117975 | Melanocortin receptor polypeptides MC-3, MC-4, and MC-5 Genes encoding melanocortin receptors have been identified, isolated, cloned and localized to their chromosomal positions. These genes have been used to transfect mammalian cells lacking endogenous melanocortin receptors to induce expression. Additionally... | 09/12/2000 |
| 6100048 | Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals The present invention provides recombinant expression constructs comprising nucleic acid encoding mammalian melanocortin receptors, and mammalian cells into which said recombinant expression constructs have been introduced that express functional mammalia... | 08/08/2000 |
| 5994303 | Use of insulin and IGF-I A combination of insulin and an insulin-like growth factor I (IGF-I) as used in the manufacture of a medicament for counteracting a decrease in nitrogen balance and for counteracting a decrease in protein synthesis. The medicament can be used for the trea... | 11/30/1999 |
| 5874227 | Cyclic CRF antagonists Novel cyclic CRF antagonist peptides have the amino acid sequence: ##STR1## wherein Y is Ac, H, Ac-Thr or H-Thr; R30 is Glu or Cys; R32 is His or preferably a basic and/or aromatic D-amino acid such as D-His or D-Arg; R33 | 02/23/1999 |
| 5869450 | Anti-inflammatory compositions and method with corticotropin-releasing factor analogs Peptide analogues are provided with amino acid sequences of the corticotropin-releasing factor superfamily, but having at least one amino acid residue that has been replaced with a D-amino acid residue or a D-amino acid analog. The peptide analogues have ... | 02/09/1999 |
| 5849871 | -melanocyte stimulating hormone receptor The present invention relates to a mammalian alpha-melanocyte stimulating hormone receptor. The invention is directed toward the isolation, characterization and pharmacological use of mammalian melanocyte stimulating hormone receptor, the gene correspondi... | 12/15/1998 |
| 5844074 | Cyclic CRF agonists Novel cyclic CRF agonist peptides have the amino acid sequence: (cyclo 30-33)Ac-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu -Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-R30 -Ala-R32 -R33 -Asn-Arg-Lys-Leu-N... | 12/01/1998 |
| 5830866 | Corticotropin release inhibiting factor and methods of using same The invention features a substantially pure preparation of a peptide having corticotropin release inhibiting factor (CRIF) activity comprising at least three contiguous amino acids contained within the amino acid sequence positioned between the fourth and... | 11/03/1998 |
| 5824771 | Cyclic CRF agonists Novel cyclic CRF agonist peptides have the amino acid sequence: (cyclo 30-33)Ac-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu -Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-R30 -Ala-R32 -R33 -Asn-Arg-Lys-Leu-N... | 10/20/1998 |
| 5777073 | Cyclic CRF antagonist peptides Novel cyclic CRF antagonist peptides are created by shortening the N-terminus of a CRF family peptide by 8-11 residues and adding an acyl group. CML is preferably present in what would be the 27-position of the native CRF sequence, and D-Tyr may be incorp... | 07/07/1998 |
| 5760187 | Purification process of a human growth hormone A human growth hormone can be purified by allowing a solution containing the human growth hormone to contact with a blue pigment-bonded carrier in order to selectively adsorb the human growth hormone, then eluting the human growth hormone with an eluant o... | 06/02/1998 |
| 5756463 | Use of insulin and IGF-1 A method is disclosed for counteracting a decrease in nitrogen balance and counteracting a decrease in protein synthesis in an individual, comprising administering to the individual a combination of insulin and IGF-I.... | 05/26/1998 |
| 5663292 | Cyclic CRF analogs Improved CRF antagonist peptides have the formula: ##STR1## wherein R30 is Cys or Glu; R33 is Cys, Lys or Orn; provided that when R30 is Cys, R33 is Cys and when R30 is Glu, R33 is Lys... | 09/02/1997 |
| 5587462 | Brain-derived membrane-associated CRF binding proteins Isolated, substantially pure mammalian brain-derived membrane-associated CRF-binding proteins and biologically active fragments thereof are provided as well as isolated and purified DNA fragments which encode the CRF binding proteins or biologically activ... | 12/24/1996 |
| 5552520 | Therapeutic peptide derivatives Peptide derivatives containing one or more substituents separately linked by an amide, amino or sulfonamide bond to an amino group on either the N-terminal end or side chain of a biologically active peptide moiety. The peptide derivatives have relatively ... | 09/03/1996 |
| 5510458 | CRF antagonists Disclosed are improved CRF peptide antagonists such as those having the formula: Y-D-Phe-Xaa13 -Leu-Leu-Arg-Xaa17 -Xaa18 -Leu-Xaa20 -Nle-Xaa22 -Xaa23 -Xaa24 -Xaa25 -Xa... | 04/23/1996 |
| 5493006 | Cyclic CRF analogs Improved CRF peptide antagonists have the formula: ##STR1## wherein R20 is Cys or Glu; R23 is Cys, Lys or Orn; provided that when R20 is Cys, R23 is Cys and when R20 is Glu, R23 is Lys... | 02/20/1996 |
| 5488033 | Treatment to reduce edema Administration of a corticotropin-releasing factor (or a salt or analog thereof) decreases the leakage of blood components into tissues produced by various adverse medical conditions. Thus, treatments with corticotropin-releasing factor are useful in syst... | 01/30/1996 |
| 5428128 | Site specific synthesis of conjugated peptides Processes for synthesizing polypeptides containing substantially non-antigenic polymers, preferably poly(alkylene glycols) in specifically predetermined sites are disclosed. Polypeptides prepared by such processes acre also disclosed.... | 06/27/1995 |
| 5428023 | Oral delivery of biologically active substances bound to vitamin B12 or analogues thereof An orally administered complex of a drug, hormone, bio-active peptide, or immunogen with the carrier molecule, such as vitamin B12 or analogue thereof, and a method for delivering said complex to the intestine of a host vertebrate in order to deliver the ... | 06/27/1995 |
| 5380710 | Pharmaceutical compositions containing ACTH (1-24) for the therapy of shock conditions and respiratory and cardiocirculatory insufficiences Pharmaceutical compositions containing ACTH(1-24) are effective in the treatment of shock conditions and of respiratory and cardiocirculatory insufficiency. The compositions of the invention may be administered by parenteral or inhalatory route at a dosag... | 01/10/1995 |
| 5306710 | Method for treating endotoxin shock with CRF Administration of a Corticotropin-Releasing Factor (or a salt or analog thereof) decreases the leakage of blood components into brain tissue produced by various adverse medical conditions and reduces bleeding when muscle tissues are cut and handled, such ... | 04/26/1994 |
| 5278146 | CRF analogs Analogs of CRF, which are based upon hCRF, oCRF, sauvagine and alpha-helical CRF, are disclosed that can be administered to achieve a substantial elevation of ACTH, ଲ-endorphin, ଲ-lipotropin, other products of the pro-opiomelanocortin gene and... | 01/11/1994 |
| 5245009 | CRF antagonists Disclosed are improved CRF peptide antagonists such as those having the formula: Y-D-Phe-R13 -Leu-Leu-Arg-R17 -R18 -Leu-R20 -Nle-R22 -R23 -R24 -R25 -R26 -Leu-R | 09/14/1993 |
| 5235036 | CRF analogs Analogs of CRF, which are based upon hCRF, oCRF and alpha-helical CRF, are disclosed that can be administered to achieve a substantial elevation of ACTH, ଲ-endorphin, ଲ-lipotropin, other products of the pro-opiomelanocortin gene and corticoste... | 08/10/1993 |
